Bimekizumab for treating active psoriatic arthritis (TA916)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2023
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2023
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 August 2022
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 October 2021
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 September 2021
Risankizumab for treating moderate to severe plaque psoriasis (TA596)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 August 2019
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 April 2019
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 April 2019
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2019
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 October 2018
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2018
Guselkumab for treating moderate to severe plaque psoriasis (TA521)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2018
Brodalumab for treating moderate to severe plaque psoriasis (TA511)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 March 2018
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 May 2017
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2017
Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 March 2017Published: 23 September 2009
Ustekinumab for treating active psoriatic arthritis (TA340)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 March 2017Published: 4 June 2015
Apremilast for treating active psoriatic arthritis (TA433)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2017
Apremilast for treating moderate to severe plaque psoriasis (TA419)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 November 2016
Secukinumab for treating moderate to severe plaque psoriasis (TA350)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Golimumab for the treatment of psoriatic arthritis (TA220)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2011
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2010
Adalimumab for the treatment of adults with psoriasis (TA146)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2008
Infliximab for the treatment of adults with psoriasis (TA134)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2008
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2006
Spesolimab for treating generalised pustular psoriasis flares [ID3963]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 19 March 2025
CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis TS ID 11773Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis TS ID 11790Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 TS ID 11921Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab biosimilar for treating plaque psoriasis TSID 11992Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC